Nootropics & Neuroprotection
CAS
153931-84-9
Molecular Weight
480
Da
A synthetic nootropic peptide built on the Semax backbone with two pharmacokinetic modifications: N-terminal acetylation to slow enzymatic degradation, and a C-terminal adamantane group borrowed from P21 to improve blood-brain barrier penetration and extend half-life. No published study of Adamax exists in any species. All proposed mechanisms are structural inferences from parent compounds Semax and P21. Among the least-evidenced compounds in the catalog — not because the rationale is implausible, but because it simply has not been studied.
Injectable · Nasal
Intranasal Suitable
Uncertain
Research Compound
We break down one compound like this every week.
Subscribe free to The Honest Dose, and get the RQS Reference, every compound in the catalog scored on one page, as a welcome gift.
Community reports from nootropic forums describe Adamax as producing stronger and longer-lasting cognitive effects than Semax, with users noting enhanced focus, improved verbal fluency, and mood elevation. Duration is anecdotally reported as 12-24 hours per dose versus 6-12 for Semax. These reports are unverifiable and cannot be distinguished from placebo response, expectation bias, or the influence of vendor marketing. PeptideClear surfaces them as community signal only, not as evidence.
Adamax is a synthetic heptapeptide analog of Semax, which is itself derived from the 4-10 fragment of adrenocorticotropic hormone (ACTH). The compound was developed within the Russian nootropic peptide research tradition. The same lineage that produced Semax at the Institute of Molecular Genetics of the Russian Academy of Sciences as an attempt to improve on Semax's primary pharmacokinetic limitation: a short half-life of roughly 30-60 minutes per intranasal dose.
Two chemical modifications define Adamax. First, N-terminal acetylation blocks aminopeptidase degradation at the amino terminus, slowing breakdown after administration. Second, a C-terminal adamantane group, a rigid, lipophilic cage hydrocarbon improves membrane permeability and resistance to proteolytic enzymes. The adamantane modification is the same chemical strategy used in approved CNS drugs amantadine and memantine to improve central nervous system bioavailability.
The compound is sometimes described as combining the Semax backbone with the adamantyl portion of P21, another nootropic peptide studied for BDNF-related effects. Adamax is not a natural or endogenous compound and has no regulatory approval in any country.
Adamax has no independently measured mechanism of action. The proposed mechanism is entirely inferred from its parent compounds.
Semax is known to upregulate BDNF (brain-derived neurotrophic factor) expression and activate the TrkB receptor in hippocampal neurons, with downstream effects on dopaminergic and serotonergic neurotransmitter systems. The acetyl modification on Adamax is expected to slow its proteolytic breakdown, and the adamantane group is expected to enhance lipophilicity and blood-brain barrier penetration both based on established principles of medicinal chemistry, not measured data for this compound specifically.
Whether Adamax actually increases BDNF, at what dose, with what potency relative to Semax, and with what duration of action has never been tested. All claimed mechanism data is either vendor-generated or inferred.
No validated use cases exist. The compound is studied, where it is studied at all, as a research tool for investigating neuroprotective mechanisms, with interest areas including: cognitive enhancement, neuroprotection, ischemic stroke recovery, neurodegenerative disease models, and stress-related brain dysfunction. These are extrapolations from Semax's established research areas, not Adamax-specific evidence.
No human safety data exists for Adamax. No toxicology studies have been published. Side effects cannot be characterized from available evidence.
Risks inferred from the Semax parent compound include: overstimulation, anxiety, and sleep disruption at higher doses. The adamantyl modification may alter how the compound behaves in the body compared to Semax, but whether that introduces new risk factors is unknown.
Research compound only. Not for human consumption.
Available as a lyophilized powder from gray-market research chemical vendors. Typically reconstituted for subcutaneous injection or intranasal administration. No standardized formulation exists. No pharmaceutical-grade source is available.
Adamax has no regulatory approval in any country. It is not on the FDA's 503A Bulks List and has not been presented to the FDA Pharmacy Compounding Advisory Committee. It is not a scheduled substance in the United States and is sold legally as a research chemical not for human use. WADA prohibited list status: not specifically listed, but may fall under the catch-all peptide hormone prohibition depending on sporting body interpretation.
https://www.scirp.org/reference/referencespapers?referenceid=1027571
Enjoyed this profile? Get one compound broken down in depth every week in The Honest Dose.
Last Reviewed